FirsthandHealth
FDA Press AnnouncementsUnited States17 November 2026

FDA launches Global Reliance Disclosure Program to share drug approval packages with international regulators

On November 17, 2026, the U.S. Food and Drug Administration announced the Global Reliance Disclosure Program. Under this initiative, the FDA will provide minimally redacted approval packages directly to drug companies. Companies can then pass these scientific reviews to health authorities outside the United States. This system helps foreign regulatory bodies rely on FDA evaluations rather than repeating time-consuming reviews on their own. The FDA launched the program on October 30, 2026, starting with a PEPFAR tentative approval for lenacapavir. Currently, the option is limited to PEPFAR tentative approvals, excluding certain generic applications. The agency plans to expand access in January 2027 to cover all novel drugs and biological products. To participate, drug makers must apply within 10 calendar days of receiving approval and confirm that the documents will support an application to a foreign health agency. Requests submitted for other purposes must use standard Freedom of Information Act channels.

What was announced

The U.S. Food and Drug Administration established an initiative called the Global Reliance Disclosure Program. Under this program, the agency shares minimally redacted approval packages with drug manufacturers. These packages contain the FDA's detailed scientific and regulatory assessments. Manufacturers can pass these documents to foreign health authorities to support marketing applications abroad.

Initial program activities began on October 30, 2026. Its first release involved a President's Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir. Eligibility is currently limited to PEPFAR tentative approvals, excluding generic abbreviated new drug applications. In January 2027, the FDA plans to expand the program to include all new molecular entity drug applications and biologics license applications. In early 2027, the agency intends to add a path for already approved drugs and biologics.

To receive these packages, companies must submit a request within 10 calendar days of approval. They must confirm that the file will be sent to an international regulator.

What it means

Patients in lower-resource countries often wait months or years for new medicines after FDA approval because local agencies lack resources for full reviews. By sharing detailed evaluation files, the FDA allows foreign health authorities to rely on U.S. scientific reviews while keeping their own regulatory authority intact. This process can speed up local decisions and reduce duplicative testing.

FDA leaders noted that shared standards across international markets help protect public health. Requests not meeting the strict 10-day deadline or intent requirements must still go through the standard Freedom of Information Act process, which usually takes longer.

What the announcement does not tell us

This release does not state how many calendar days the FDA will take to deliver the minimally redacted packages after receiving a request. It only notes the agency intends to provide them on an expedited basis.

Specific redaction criteria are missing from the announcement, so it is unclear what standard commercial information will be removed from the approval packages. Furthermore, the agency does not list which foreign regulatory authorities have formally agreed to accept or rely on these FDA packages. Finally, the text does not outline the precise launch date or process for the early 2027 pathway covering existing market products.

How this was written

This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA Press Announcements’s own. Always check the original before acting on anything here.

FDA today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities around the world.
Source: FDA Press Announcements

More from FDA Press Announcements

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.